Featured Research

from universities, journals, and other organizations

Rare Immune Cell Is Key To Transplant's Cancer-killing Effect

Date:
October 17, 2005
Source:
University of Michigan Health System
Summary:
University of Michigan researchers have discovered the secret weapon behind the most powerful form of cancer immunotherapy known to medicine. Scientists call it the graft-versus-leukemia effect, and it occurs when new immune cells from donated bone marrow, called the graft, attack malignant cells in the patient and destroy them. This intense immune reaction between donor and host cells, which follows a bone marrow transplant from a healthy donor, has saved the lives of thousands of patients with leukemia, lymphoma and other types of blood and immune system cancers.

An antigen presenting cell interacting with two T cells.
Credit: Pavan Reddy, U-M Medical School

ANN ARBOR, Mich. -- Researchers at the University of Michigan'sComprehensive Cancer Center have discovered the secret weapon behindthe most powerful form of cancer immunotherapy known to medicine.

Scientists call it the graft-versus-leukemia effect, and it occurs whennew immune cells from donated bone marrow, called the graft, attackmalignant cells in the patient and destroy them. This intense immunereaction between donor and host cells, which follows a bone marrowtransplant from a healthy donor, has saved the lives of thousands ofpatients with leukemia, lymphoma and other types of blood and immunesystem cancers.

In a study to be published Oct. 16 in the advanced onlineedition of Nature Medicine, U-M scientists describe how antigenpresenting cells are crucial to graft-versus-leukemia's cancer-killingeffect.

The discovery is significant, because it could help make cellularimmunotherapy safer, more effective and an option for more cancerpatients -- especially those for whom a donor is unavailable or thosewho cannot tolerate the procedure's side-effects.

"We already knew that donor T cells were important for aneffective GVL response, but now we know there's another cell -- theantigen presenting cell or APC -- which plays a critical role in theprocess," says James L.M. Ferrara, M.D., who directs the U-M CancerCenter's Blood and Marrow Transplant Program.

Antigen presenting cells are rare immune system cells, which looksomething like a starfish. Their job is to digest proteins calledantigens from foreign cells or pathogens and present them to T cells.This alerts the immune system to prepare to fight the invader. WhenAPCs present cancer cell proteins to T cells, the T cells are primed toattack the cancer.

"We found that without functional APCs to process and presentantigens to T cells, there is no graft-versus-leukemia response, andthe cancer is likely to return," says Pavan R. Reddy, M.D., anassistant professor of internal medicine in the University of MichiganMedical School, who led the research study.

According to Reddy, the research results suggest that manipulating thenumber and activity of APCs could improve the GVL response, whilereducing the risk of a common post-transplant complication calledgraft-versus-host disease, or GVHD.

"GVHD occurs when the donor's immune cells attack thepatient's skin, liver and gastrointestinal tract," Reddy explains. "Ittriggers a massive inflammatory reaction that can kill the patient,especially if he or she is older or has other medical problems."

In an effort to eliminate GVHD, other researchers havesuggested removing APCs from transplanted donor cells, according toFerrara. "We know that APCs are involved in graft-versus-host disease,so people say let's take out the APCs and then we will get theanti-cancer effect without the risk of GVHD," he explains. "This papersays, no, you can't do that.

"There's a tight link between the graft-versus-leukemia effectand graft-versus-host disease," Ferrara says. "Few patients get thebeneficial effects of GVL without some degree of the toxic side effectsof GVHD. But if we can find ways to reduce GVHD's toxic effects,immunotherapy could become a viable option for many more cancerpatients."

To study what happens during the graft-versus-leukemia effect,Reddy and his U-M colleagues used high doses of radiation to destroythe blood and immune systems of genetically different laboratory mice.After reconstituting each animal's immune system, using eitherfunctional or non-functional APCs, the mice were inoculated with cancercells and given a bone marrow transplant that could cure the cancer.The scientists then determined which mice died from acutegraft-versus-host disease, which mice died from cancer and which micegenerated a GVL response to destroy the cancer cells.

"The donor and host mice were paired in ways to make theirantigen-presenting cells dysfunctional, either because they were of thesame tissue type as the donor, or because they had a mutation thatprevented them from displaying tumor antigens to T cells," Reddyexplains. "Essentially we created animals where the tumor was the same,the antigens were the same, donor T cells were the same, but the APCwas dysfunctional. Without a functioning APC, there was nograft-versus-leukemia effect."

Other researchers have suggested that tumor cells can presentantigens to T cells directly to stimulate an immune response againstcancer, but results from the U-M study indicate the response is tooweak to be effective.

"APCs shred proteins, or antigens, from cancer cells anddisplay those shredded proteins on their surface," Ferrara says."Cancer cells have the same proteins, but haven't gone through theAPC's shredding process. It's as if APCs are master chefs who preparethe antigens in a way to make them especially delicious to T cells. Soinstead of taking just one bite, they go back for seconds or thirds."

In future research, U-M scientists will explore how tomanipulate APC function in ways that will preserve their vital role instimulating an immune response against cancer, while controlling theintensity of graft-versus-host disease. Reddy and Ferrara have studieddrugs called HDAC inhibitors and found that they modulate APC functionin mice. They hope to design an initial study of these drugs inpost-transplant leukemia patients within a year.

###

The research was funded by the National Cancer Institute.Collaborators included Yoshinobu Maeda, M.D., a former U-M researchfellow; Oleg I. Krijanovski, M.D., a research fellow in internalmedicine; Chen Liu, M.D., a pathologist at the University of FloridaCollege of Medicine; and Robert Korngold, M.D., Ph.D., an immunologistand scientific director of the Hackensack University Cancer Center.


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Cite This Page:

University of Michigan Health System. "Rare Immune Cell Is Key To Transplant's Cancer-killing Effect." ScienceDaily. ScienceDaily, 17 October 2005. <www.sciencedaily.com/releases/2005/10/051017072731.htm>.
University of Michigan Health System. (2005, October 17). Rare Immune Cell Is Key To Transplant's Cancer-killing Effect. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2005/10/051017072731.htm
University of Michigan Health System. "Rare Immune Cell Is Key To Transplant's Cancer-killing Effect." ScienceDaily. www.sciencedaily.com/releases/2005/10/051017072731.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins